Skip to main content
. 2020 Jul 11;12(7):1867. doi: 10.3390/cancers12071867

Table 2.

Treatment response rate of Lenvatinib (LEN).

Response Category Patients with HCC Treated with Lenvatinib (n = 177)
CR 6 (3%)
PR 57 (32%)
SD 72 (41%)
PD 42 (24%)
ORR 63 (38%)
DCR 135 (76%)

Data are expressed as frequency (percentage). Abbreviations: HCC, hepatocellular carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.